RM Global Partners

What is RM Global Partners?

RM Global Partners, established in 1992 with bases in New York and Herzliya, Israel, is a premier investment banking and strategic advisory firm immersed in the life sciences sector. Their unrivaled acumen covers a broad array of subdomains such as pharmaceuticals, biotechnology, medical devices, healthcare IT/digital health, and diagnostics.

They cater to a geographically diversified clientele across the Americas, Europe, Israel, and Asian markets including Korea, Japan, and China. RM Global boasts a holistic suite of services encompassing M&A advisory, venture, growth, bridge, and private equity financing, valuation, transaction structures, deal tactics and negotiations, as well as corporate venture capital management.

Furthermore, the firm plays a pivotal role in technology transfer and portfolio enhancement by offering in-licensing and out-licensing services. RM Global Partners also manages the RMGP Biopharma Investment Fund, a venture capital entity that strategically invests in innovative, early-stage biopharma assets.

This VC initiative is significantly fortified through RMGP's partnership with FutuRx—an Israel-based, globally oriented drug development platform collaboratively established by healthcare giants Orbimed, Johnson & Johnson, and Takeda.

This alliance is instrumental in accessing meticulously curated projects with the potential to emerge as first-in-class or best-in-class treatments targeting therapeutic areas with a high degree of unmet medical needs, including oncology, rare diseases, autoimmune disorders, cardiovascular and metabolic diseases, neurodegenerative and other CNS ailments.

RM Global's investment philosophy mirrors their commitment to advancing healthcare by injecting funds within the range of $20 million, meticulously positioning themselves at the vanguard of transformative life sciences ventures with profound growth prospects.